公开(公告)号：US20240277824A1

公开(公告)日：2024-08-22

申请号：US18402174

申请日：2024-01-02

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Fabiana FERNANDEZ ,  Michael KOWARIK ,  Michael WACKER ,  Michael WETTER

IPC: A61K39/112 ,  A61K39/00 ,  A61K39/02 ,  A61K39/104 ,  A61K39/108 ,  A61K39/385 ,  C07K14/195

CPC classification number: A61K39/0283 ,  A61K39/0258 ,  A61K39/104 ,  A61K39/105 ,  A61K39/385 ,  C07K14/195 ,  A61K2039/6037 ,  A61K2039/6068 ,  A61K2039/6087 ,  C07K2319/034 ,  Y02A50/30

Abstract: The present invention is directed to a bioconjugate vaccine, such as an O 1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, DIE-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O 1-bioconjugate in a bioreactor comprising a number steps.

公开(公告)号：US12049484B2

公开(公告)日：2024-07-30

申请号：US18186724

申请日：2023-03-20

Applicant: Stichting Amsterdam UMC

Inventor： Arjan Willem Griffioen ,  Elisabeth Johanna Maria Huijbers ,  Patrycja Nowak-Sliwinska

IPC: A61K39/00 ,  A61P35/00 ,  C07K14/245 ,  C07K14/47 ,  C07K14/78 ,  C07K16/18 ,  C12N15/62 ,  C12Q1/6886

CPC classification number: C07K14/4748 ,  A61K39/0011 ,  A61P35/00 ,  C07K14/245 ,  C07K14/78 ,  C07K16/18 ,  C12N15/62 ,  C12Q1/6886 ,  A61K2039/55566 ,  A61K2039/585 ,  A61K2039/6068 ,  C07K2319/21 ,  C07K2319/35 ,  C12Q2600/106 ,  C12Q2600/112

Abstract: The invention is in the field of medicine. More specifically, it is in the field of diagnosing tumor angiogenesis status and in the field of medical treatment of a subject who is suffering, suspected to suffer, or might suffer from a tumor in the future. In particular, the invention relates to a fusion polypeptide comprising a foreign antigen and a self antigen, wherein said foreign antigen consists of a polypeptide comprising an amino acid sequence of at least 12-15 amino acid residues, 12-24% of which residues are hydrophilic, bulky amino acid residues selected from the group consisting of histidine, glutamate, arginine, glutamine, aspartic acid and/or lysine.

公开(公告)号：US20240226012A1

公开(公告)日：2024-07-11

申请号：US18615895

申请日：2024-03-25

Applicant: The USA, as represented by the Secretary, Department of Health and Human Services

Inventor： Barney S. Graham ,  Masaru Kanekiyo ,  Hadi M. Yassine

IPC: A61K9/16 ,  A61K39/00 ,  A61K39/12 ,  A61K39/145 ,  C12N7/00

CPC classification number: A61K9/167 ,  A61K39/12 ,  A61K39/145 ,  C12N7/00 ,  A61K2039/575 ,  A61K2039/6031 ,  A61K2039/6068 ,  A61K2039/6075 ,  A61K2039/70 ,  C12N2760/16134 ,  C12N2760/16171 ,  Y02A50/30

Abstract: Novel, nanoparticle-based vaccines are provided that elicit an immune response to a broad range of infectious agents, such as influenza viruses. The nanoparticles comprise a heterogeneous population of fusion proteins, each comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to one or more immunogenic portions of a protein from an infectious agent, such as influenza virus. The fusion proteins self-assemble to form nanoparticles that display a heterogeneous population of immunogenic portions on their surface. When administered to an individual, such nanoparticles elicit an immune response to different strains, types, subtypes and species with in the same taxonomic family. Thus, such nanoparticles can be used to vaccinate an individual against infection by different Types, subtypes and/or strains of infectious agents. Also provided are specific fusion proteins, nucleic acid molecules encoding such fusion proteins and methods of using nanoparticles of the invention to vaccinate individuals.

公开(公告)号：US11986519B2

公开(公告)日：2024-05-21

申请号：US17569304

申请日：2022-01-05

Applicant: Eva Barbara Schadeck

Inventor： Bruce D. Forrest

IPC: A61K39/00 ,  A61K39/102 ,  A61P31/04

CPC classification number: A61K39/102 ,  A61P31/04 ,  A61K2039/55505 ,  A61K2039/575 ,  A61K2039/6018 ,  A61K2039/6037 ,  A61K2039/6068

Abstract: Provided herein are Haemophilus influenzae saccharide-carrier conjugates and compositions thereof. Also provided are methods of making and using the conjugates and compositions thereof, and kits containing the conjugates. Haemophilus influenzae saccharide-lipid conjugates, Haemophilus influenzae saccharide-glycosphingolipid conjugates, compositions containing these, methods of making and using the conjugates and compositions, and kits containing these, are also disclosed. Saccharide-lipid conjugates, and saccharide-glycosphingolipid conjugates comprising saccharides from Haemophilus influenzae serotype a, as well as compositions containing these, methods of making and using the conjugates and compositions, and kits containing these, are also disclosed.

公开(公告)号：US11890336B2

公开(公告)日：2024-02-06

申请号：US17098809

申请日：2020-11-16

Applicant: London School of Hygiene and Tropical Medicine

Inventor： Brendan Wren ,  Jon Cuccui ,  Madeleine Moule

IPC: A61K39/00 ,  A61K39/02 ,  A61K47/64 ,  A61P31/04 ,  C07K14/195 ,  C12N15/74

CPC classification number: A61K39/0208 ,  A61K47/646 ,  A61P31/04 ,  C07K14/195 ,  C12N15/74 ,  A61K2039/55566 ,  A61K2039/55572 ,  A61K2039/575 ,  A61K2039/6037 ,  A61K2039/6068 ,  A61K2039/70 ,  C07K2319/40

Abstract: The disclosure relates to a glycoconjugate vaccine conferring protection against Francisella tularensis infections and a method to manufacture a glycoconjugate antigen.

公开(公告)号：US11723965B2

公开(公告)日：2023-08-15

申请号：US17395108

申请日：2021-08-05

Applicant: PFIZER INC.

Inventor： Jianxin Gu ,  Jin-hwan Kim ,  Avvari Krishna Prasad ,  Yu-ying Yang

IPC: A61K39/095 ,  A61K47/64 ,  A61K39/09 ,  A61K45/06 ,  A61K39/00

CPC classification number: A61K39/095 ,  A61K39/092 ,  A61K45/06 ,  A61K47/64 ,  A61K47/646 ,  A61K47/6415 ,  A61K2039/6037 ,  A61K2039/6068 ,  A61K2039/627

Abstract: The invention provides eTEC linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, immunogenic compositions comprising such glycoconjugates, and methods for the preparation and use of such glycoconjugates and immunogenic compositions.

公开(公告)号：US11648306B2

公开(公告)日：2023-05-16

申请号：US17050666

申请日：2019-04-23

Applicant: Suzhou RoyalTech Med CO., Ltd ,  Shanghai RoyalTech Med CO., Ltd

Inventor： Nan Dai ,  Yonggang Zhao

IPC: A61K39/385 ,  A61P35/00 ,  A61K39/00 ,  A61K39/02 ,  A61K45/06 ,  C07K14/195 ,  C07K14/47 ,  C07K14/77

CPC classification number: A61K39/385 ,  A61K39/0011 ,  A61K39/0208 ,  A61K45/06 ,  A61P35/00 ,  C07K14/195 ,  C07K14/4748 ,  C07K14/77 ,  A61K2039/522 ,  A61K2039/523 ,  A61K2039/585 ,  A61K2039/6068 ,  A61K2039/6081 ,  C07K2319/55

Abstract: Disclosed are a non-integrative Listeria-based vaccine and a method for inducing antitumor immune response. In particular, the present disclosure provides a recombinant nucleic acid molecule, a recombinant plasmid or a recombinant expression vector comprising the recombinant nucleic acid molecule, a recombinant protein, and a recombinant Listeria. Also disclosed are a pharmaceutical composition and a vaccine comprising the above component, a method for slowly and continuously killing cells using the same, and a method for inducing immune response in a subject using the same.

公开(公告)号：US20180207262A1

公开(公告)日：2018-07-26

申请号：US15869742

申请日：2018-01-12

Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.

Inventor： Ralph Leon BIEMANS ,  Nathalie Marie-Josephe GARCON ,  Philippe Vincent HERMAND ,  Jan POOLMAN ,  Marcelle Paulette VAN MECHELEN

IPC: A61K39/385 ,  A61K47/64 ,  A61K39/09 ,  A61K39/00

CPC classification number: A61K39/385 ,  A61K39/092 ,  A61K47/61 ,  A61K47/6415 ,  A61K47/646 ,  A61K2039/545 ,  A61K2039/55 ,  A61K2039/555 ,  A61K2039/55566 ,  A61K2039/575 ,  A61K2039/6031 ,  A61K2039/6037 ,  A61K2039/6068 ,  A61K2039/6087 ,  A61K2039/62 ,  A61K2039/627 ,  A61K2039/70 ,  Y02A50/412

Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, an immunogenic composition for infants is provided comprising a multivalent Streptococcus pneumoniae vaccine comprising 2 or more capsular saccharide conjugates from different serotypes, wherein the composition comprises a serotype 22F saccharide conjugate. Such a vaccine may be used in infant populations to reduce the incidence of elderly pneumococcal disease such as exacerbations of COPD and/or IPD.

公开(公告)号：US20180177869A1

公开(公告)日：2018-06-28

申请号：US15845306

申请日：2017-12-18

Applicant: United States of America as Represented by Secretary of Agriculture

Inventor： Richard Mauldin ,  Doug Eckery ,  Lowell Miller

IPC: A61K39/39 ,  A61K39/00 ,  A61K35/74 ,  A61P15/16 ,  A61P15/18

CPC classification number: A61K39/39 ,  A61K35/74 ,  A61K39/0006 ,  A61K39/04 ,  A61K2039/54 ,  A61K2039/552 ,  A61K2039/55594 ,  A61K2039/6068 ,  A61P15/16 ,  A61P15/18

Abstract: A vaccine adjuvant and immunogenic composition may be described herein. The vaccine adjuvant may comprise cell wall fragments of the genus Mycobacterium, and more particularly, of M avium. The immunogenic composition may include the vaccine adjuvant conjugated to an antigen. For example, cell wall fragments of M. avium (herein also referred to as MAF) may be conjugated to an antigen targeting Gonadotropin releasing hormone (GnRH). The MAF-antigen conjugate may be delivered for the purposes of treatment through one of several methods, including intramuscular injection, naso-pharyngeal, or oral.

公开(公告)号：US10004799B2

公开(公告)日：2018-06-26

申请号：US15447972

申请日：2017-03-02

Applicant: Longhorn Vaccines and Diagnostics, LLC

Inventor： Gerald W. Fischer ,  Luke T. Daum

IPC: A61K39/145 ,  C07K14/33 ,  A61K39/12 ,  A61K39/04 ,  C07K14/35 ,  C07K16/10 ,  C07K16/12 ,  C12N7/00 ,  A61K39/00 ,  C07K14/005

CPC classification number: A61K39/145 ,  A61K39/04 ,  A61K39/12 ,  A61K2039/525 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/53 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/55566 ,  A61K2039/575 ,  A61K2039/6037 ,  A61K2039/6043 ,  A61K2039/6068 ,  A61K2039/70 ,  C07K14/005 ,  C07K14/33 ,  C07K14/35 ,  C07K16/1018 ,  C07K16/1289 ,  C07K2319/40 ,  C07K2319/42 ,  C12N7/00 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12N2760/16161

Abstract: The invention relates to composite antigens comprising a peptide with contiguous amino acid sequence derived from a plurality of antigenic epitopes of one or more pathogens that induces an immune response in a mammal that is protective against infection by the one or more pathogens. In addition, the invention relates to vaccines comprising composite antigens and to method for treating and preventing an infection.